Erlinge D, Andersson J, Fröbert O, et al. Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, ...

Stent selection and concomitant antithrombotic strategies are the key considerations when finding the best balance between these opposite threats. Drug-eluting stents should be avoided or strictly ...

[Image from the SpyGlass Pharma website] SpyGlass Pharma released 18-month follow-up data highlighting the potential of its intraocular lens (IOL)-based drug delivery platform. Data came from a ...

Drugs such as Novo Nordisk’s blockbuster Ozempic can cut drug and alcohol abuse by up to 50% according to a new study, adding to mounting evidence that the drugs yield health benefits beyond ...

Established in 1993 by Dhirajlal Kotadia, SMT currently holds a 31 per cent share of the drug-eluting stent (DES) market in India and has been expanding its presence in Europe. In FY24, the company ...

Finally, Dr. Eagle discusses short-term dual antiplatelet therapy (DAPT) after drug-eluting stenting in patients with acute coronary syndrome (ACS).

The ChampioNIR Drug-Eluting Peripheral Stent System poses a transformational technology designed to improve patient outcomes and procedural success. In a first of its kind hybrid mechanical design ...

Over the past decade, drug-eluting stents (DES) have greatly transformed the field of interventional cardiology. Generally, three components are included in a DES system: a metal stent platform ...

More recently, drug-eluting stents (DESs) have emerged as the predominant percutaneous strategy in patients with coronary artery disease. This Review summarizes the knowledge on coronary stenting ...